Oxford BioMedica - Public Comps and Valuation Multiples

Oxford BioMedica Overview

About Oxford BioMedica

Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types.

Founded

1996

HQ

Employees

861

Website

oxb.com

Sectors

Contract Research & Manufacturing
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $210M

LTM EBITDA $1.3M

EV

$1.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Oxford BioMedica Financials

As of September 2025, Oxford BioMedica reported last 12-month revenue of $210M and EBITDA of $1.3M.

In the same period, Oxford BioMedica generated $96.1M in LTM gross profit and -$40.5M in net income.

See Oxford BioMedica valuation multiples based on analyst estimates

Oxford BioMedica P&L

In the most recent fiscal year, Oxford BioMedica reported revenue of $172M and EBITDA of -$19.1M.

Oxford BioMedica expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Oxford BioMedica valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$210M	XXX	$172M	XXX	XXX	XXX
Gross Profit	$96.1M	XXX	$70.7M	XXX	XXX	XXX
Gross Margin	46%	XXX	41%	XXX	XXX	XXX
EBITDA	$1.3M	XXX	-$19.1M	XXX	XXX	XXX
EBITDA Margin	1%	XXX	-11%	XXX	XXX	XXX
EBIT	-$32.1M	XXX	-$58.0M	XXX	XXX	XXX
EBIT Margin	-15%	XXX	-34%	XXX	XXX	XXX
Net Profit	-$40.5M	XXX	-$57.6M	XXX	XXX	XXX
Net Margin	-19%	XXX	-34%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Oxford BioMedica including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $210M. EBITDA for the last twelve months was $1.3M. In the most recent fiscal year, Oxford BioMedica achieved $172M in revenue and -$19.1M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$210M	Analyst estimates available to subscribers	$172M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$96.1M	Analyst estimates available to subscribers	$70.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	45.8% gross margin	Analyst estimates available to subscribers	41.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$1.3M	Analyst estimates available to subscribers	-$19.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	0.6% EBITDA margin	Analyst estimates available to subscribers	-11.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$32.1M	Analyst estimates available to subscribers	-$58.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-15.3% EBIT margin	Analyst estimates available to subscribers	-33.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$40.5M	Analyst estimates available to subscribers	-$57.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-19.3% net profit margin	Analyst estimates available to subscribers	-33.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Oxford BioMedica

This financial data table provides comprehensive performance metrics for Oxford BioMedica, a company based in United Kingdom of Great Britain and Northern Ireland. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Oxford BioMedica generated $210M in revenue over the last twelve months.
The company achieved $1.3M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $96.1M.
Net income over the last twelve months reached -$40.5M.

Fiscal Year Performance

In the most recent fiscal year, Oxford BioMedica reported $172M in total revenue.
Fiscal year EBITDA was -$19.1M.
The company maintained a gross profit margin of 41.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was -11.1%.
Net profit margin reached -33.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Oxford BioMedica. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Oxford BioMedica Stock Performance

Oxford BioMedica has current market cap of GBP 707M (or $942M), and EV of GBP 758M (or $1.0B).

Market Cap Evolution

Oxford BioMedica Stock Data

As of October 17, 2025, Oxford BioMedica's stock price is GBP 6 (or $8).

See Oxford BioMedica trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.0B	$942M	XXX	XXX	XXX	XXX	$-0.38

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Oxford BioMedica Valuation Multiples

Oxford BioMedica's trades at 5.9x EV/Revenue multiple, and -52.9x EV/EBITDA.

See valuation multiples for Oxford BioMedica and 15K+ public comps

Oxford BioMedica Financial Valuation Multiples

As of October 17, 2025, Oxford BioMedica has market cap of $942M and EV of $1.0B.

Equity research analysts estimate Oxford BioMedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Oxford BioMedica has a P/E ratio of -23.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$942M	XXX	$942M	XXX	XXX	XXX
EV (current)	$1.0B	XXX	$1.0B	XXX	XXX	XXX
EV/Revenue	4.8x	XXX	5.9x	XXX	XXX	XXX
EV/EBITDA	786.7x	XXX	-52.9x	XXX	XXX	XXX
EV/EBIT	-31.5x	XXX	-17.4x	XXX	XXX	XXX
EV/Gross Profit	10.5x	XXX	n/a	XXX	XXX	XXX
P/E	-23.3x	XXX	-16.4x	XXX	XXX	XXX
EV/FCF	-39.0x	XXX	-13.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Oxford BioMedica Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Oxford BioMedica Margins & Growth Rates

Oxford BioMedica's last 12 month revenue growth is 33%

Oxford BioMedica's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Oxford BioMedica's rule of 40 is -133% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Oxford BioMedica's rule of X is 83% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Oxford BioMedica and other 15K+ public comps

Oxford BioMedica Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	33%	XXX	31%	XXX	XXX	XXX
EBITDA Margin	1%	XXX	-11%	XXX	XXX	XXX
EBITDA Growth	2313%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-133%	XXX	22%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	83%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	75%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial